Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Polyrizon completed enrollment and randomization of all 120 planned participants in its U.S. multicenter clinical study of NASARIX, its investigational nasal hydrogel for protection against airborne allergens. The randomized, controlled study compares NASARIX against a saline control in adults with allergic rhinitis across five U.S. clinical sites; 144 individuals were screened to hit the target.
Key figures
- Drug Name
- NASARIX
- Phase Of Trial
- U.S. multicenter randomized controlled study
- Clinical sites
- 5
- Patients enrolled
- 120
- Individuals screened
- 144
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.